Multivariate Prediction Equations for HbA1c, Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling

被引:25
作者
Willis, Michael [1 ]
Asseburg, Christian [1 ]
Nilsson, Andreas [1 ]
Johnsson, Kristina [2 ]
Kartman, Bernt [2 ]
机构
[1] Swedish Inst Hlth Econ, Box 2127, SE-22002 Lund, Sweden
[2] AstraZeneca, Gothenburg, Sweden
关键词
diabetes; HbA(1c); insulin; weight; LIFETIME HEALTH OUTCOMES; HBA1C TARGET; MANAGEMENT; THERAPIES;
D O I
10.1016/j.jval.2016.10.004
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Type 2 diabetes mellitus (T2DM) is chronic and progressive and the cost-effectiveness of new treatment interventions must be established over long time horizons. Given the limited durability of drugs, assumptions regarding downstream rescue medication can drive results. Especially for insulin, for which treatment effects and adverse events are known to depend on patient characteristics, this can be problematic for health economic evaluation involving modeling. Objectives: To estimate parsimonious multivariate equations of treatment effects and hypoglycemic event risks for use in parameterizing insulin rescue therapy in model-based cost-effectiveness analysis. Methods: Clinical evidence for insulin use in T2DM was identified in PubMed and from published reviews and meta-analyses. Study and patient characteristics and treatment effects and adverse event rates were extracted and the data used to estimate parsimonious treatment effect and hypoglycemic event risk equations using multivariate regression analysis. Results: Data from 91 studies featuring 171 usable study arms were identified, mostly for premix and basal insulin types. Multivariate prediction equations for glycated hemoglobin Alc lowering and weight change were estimated separately for insulin-naive and insulin experienced patients. Goodness of fit (R-2) for both outcomes were generally good, ranging from 0.44 to 0.84. Multivariate prediction equations for symptomatic, nocturnal, and severe hypoglycemic events were also estimated, though considerable heterogeneity in definitions limits their usefulness. Conclusions: Parsimonious and robust multivariate prediction equations were estimated for glycated hemoglobin Alc and weight change, separately for insulin-naive and insulin-experienced patients. Using these in economic simulation modeling in T2DM can improve realism and flexibility in modeling insulin rescue medication.
引用
收藏
页码:357 / 371
页数:15
相关论文
共 18 条
[1]  
[Anonymous], 2019, DIABETES CARE, V42, pS1, DOI [10.2337/dc20-Sint, 10.2337/dc19-Sint01, 10.2337/dc19-SINT01, 10.2337/dc20-SINT, 10.2337/dc16-S001]
[2]   A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) [J].
Clarke, PM ;
Gray, AM ;
Briggs, A ;
Farmer, AJ ;
Fenn, P ;
Stevens, RJ ;
Matthews, DR ;
Stratton, IM ;
Holman, RR .
DIABETOLOGIA, 2004, 47 (10) :1747-1759
[3]  
DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z
[4]   Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials [J].
DeFronzo, R. A. ;
Stonehouse, A. H. ;
Han, J. ;
Wintle, M. E. .
DIABETIC MEDICINE, 2010, 27 (03) :309-317
[5]  
Drummond MF, 2005, Methods for The Economic Evaluation of Health Care Programmes
[6]   Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7 [J].
Eddy, David M. ;
Hollingworth, William ;
Caro, J. Jaime ;
Tsevat, Joel ;
McDonald, Kathryn M. ;
Wong, John B. ;
Force, ISPOR-SMDM Modeling Good Res Practices Task .
MEDICAL DECISION MAKING, 2012, 32 (05) :733-743
[7]   Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients [J].
Esposito, K. ;
Chiodini, P. ;
Bellastella, G. ;
Maiorino, M. I. ;
Giugliano, D. .
DIABETES OBESITY & METABOLISM, 2012, 14 (03) :228-233
[8]   ASSESSING THE SIGNIFICANCE OF HBA1C DURABILITY IN COST EFFECTIVENESS ANALYSIS OF 2ND LINE ORAL THERAPIES IN THE MANAGEMENT OF TYPE 2 DIABETES [J].
Foos, V ;
McEwan, P. ;
Palmer, J. L. ;
Lamotte, M. ;
Grant, D. .
VALUE IN HEALTH, 2013, 16 (07) :A589-A589
[9]   UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 [J].
Hayes, A. J. ;
Leal, J. ;
Gray, A. M. ;
Holman, R. R. ;
Clarke, P. M. .
DIABETOLOGIA, 2013, 56 (09) :1925-1933
[10]   Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs [J].
Home, Philip D. ;
Shen, Chunduo ;
Hasan, Mohammad I. ;
Latif, Zafar A. ;
Chen, Jian-Wen ;
Gonzalez Galvez, Guillermo .
DIABETES CARE, 2014, 37 (05) :1237-1245